STOCK TITAN
  1. Home
  2. News
  3. AMGN

AMGEN Inc. - AMGN STOCK NEWS

Welcome to our dedicated news page for AMGEN (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on AMGEN.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AMGEN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AMGEN's position in the market.

News
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Rhea-AI Summary
Amgen announces positive results from Phase 3 trial of LUMAKRAS in patients with KRAS G12C-mutated colorectal cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
Rhea-AI Summary
Amgen announces positive results for tarlatamab in patients with advanced small cell lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023
Rhea-AI Summary
Amgen to host webcasted call for investment community following presentation of new data from oncology portfolio
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
News
AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
Rhea-AI Summary
Amgen presents new data at ESMO Congress 2023, highlighting potential of various therapies in tough-to-treat cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
-
News
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
Rhea-AI Summary
Amgen completes acquisition of Horizon Therapeutics for $27.8 billion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
acquisition
-
News
Large-scale proteomics in population-based studies from UK and Iceland
Rhea-AI Summary
deCODE Genetics scientists release findings from plasma proteomics study, demonstrating how it can contribute to understanding diseases. Associations found between diseases and specific proteins. Leveraging genetic factors can uncover molecular mechanisms of disease development. Data from 50,000 individuals analyzed using two platforms. Discrepancies between platforms affect biomarker discovery. Validation of individual assays necessary. deCODE is a global leader in genome analysis. Wholly-owned subsidiary of Amgen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
News
AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
Rhea-AI Summary
Amgen launches Amgen Partners of Choice network to advance collaboration in oncology research and development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
News
Variants in the genome interact with each other and with the environment to affect risk of cardiovascular disease
Rhea-AI Summary
Scientists at deCODE genetics, a subsidiary of Amgen, publish a study on the complex effects of sequence variants on lipid levels and coronary artery disease. The study shows that carriers of a particular sequence variant are protected against the negative effects of alcohol consumption on coronary artery disease. Carriers of another sequence variant are more susceptible to increases in bad cholesterol upon consumption of oily fish. The study also demonstrates that homozygotes of the APOE2 allele have high levels of bad cholesterol but fewer particles carrying the cholesterol, conferring similar risk of developing coronary artery disease as non-carriers. Blood group secretor status influences cholesterol levels and cardiovascular disease risk among individuals not in the A1 blood group. These findings highlight the complex interaction between the genome and the environment in affecting health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
News
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Rhea-AI Summary
Amgen to present at Bank of America Merrill Lynch Global Healthcare Conference on Sept. 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences
News
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
Rhea-AI Summary
Amgen announces positive data from Phase 1b study of LUMAKRAS in first-line treatment of KRAS G12C-mutated NSCLC, with a confirmed objective response rate of 65% and disease control rate of 100%. Phase 3 study initiated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock AMGN logo
AMGEN Inc.

Nasdaq:AMGN

AMGN Rankings

#73 Ranked by Market Cap
#2185 Ranked by Stock Gains
#1039 Ranked by Dividends

AMGN Stock Data

142.36B
534.35M
0.25%
80.73%
1.95%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Thousand Oaks

About AMGN

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.